Opinion

Video

Final Thoughts on CSPC

Author(s):

Stephen J. Freedland, MDEleni Efstathiou, MD, PhD

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Video content above is prompted by the following questions:

  • How do you foresee the early treatment paradigm for CSPC evolving in the coming years?
    • Are there other novel agents you're excited about in development?
    • How will their availability impact treatment sequencing strategies?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
Ruben Olivares, MD
Related Content
The OncFive: Top Oncology Articles for the Week of 9/1
September 7th 2024

The OncFive: Top Oncology Articles for the Week of 9/1

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
August 29th 2024

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Prostate Cancer
August 22nd 2024

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

Kara N. Maxwell, MD, PhD, director, Men and BRCA Program, Basser Center, associate professor, medicine (hematology-oncology), Perelman School of Medicine, University of Pennsylvania
August 20th 2024

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers